New Zealand - English - Medsafe (Medicines Safety Authority)

hospira nz ltd - cefamandole nafate 1.108 g - powder for injection - 1 g - active: cefamandole nafate 1.108 g excipient: sodium carbonate

New Zealand - English - Medsafe (Medicines Safety Authority)

hospira nz ltd - cefamandole nafate 2.216 g - powder for injection - 2 g - active: cefamandole nafate 2.216 g excipient: sodium carbonate

New Zealand - English - Medsafe (Medicines Safety Authority)

hospira nz ltd - cefamandole nafate 554mg - powder for injection - 500 mg - active: cefamandole nafate 554mg excipient: sodium carbonate

Canada - English - Health Canada

eli lilly canada inc - cefamandole (cefamandole nafate) - powder for solution - 1g - cefamandole (cefamandole nafate) 1g - second generation cephalosporins

Namibia - English - Namibia Medicines Regulatory Council

adcock ingram critical care (pty) ltd - cefamandole nafate - injection - cefamandole nafate equiv. to cefamandole 1 g sterile powder for injection

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - cefamandole, quantity: 500 mg - injection, powder for - excipient ingredients: sodium carbonate - cephamandole nafate is indicated for the treatment of the following infections when sue to susceptible organisms (see pharmacolocy: anti-bacterial activity). (1) respiratory tract infections. (2) genito-urinary tract infections. (3) peritonitis and other intra-abdominal and intra-pelvic infections. (4) septicaemia. (5) skin ans soft-tissue infections. (6) bone and joint infections. note: concentrations of cephamandole in the csf are considerably lower than in the plasma, its use in the treatment of bacterial meningitis and brain abscess is therefore not advised. indications as at 30 june 94: mandol is indicated for the treatment of serious infections of the respiratory tract, genitourinary tract, skin and soft tissue, bones and joints, septicaemia, gall bladder and peritoneum when due to susceptible strains of the above mentioned organisms. concentrations of mandol in the csf are considerably lower than in the plasma; use in the treatment of meningitis and brain abscess is therefore not advised. specimens for

New Zealand - English - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - cefamandole nafate 554mg equivalent to 500 mg cephamandole (added as intermediate with sod bic) - powder for injection - 500 mg - active: cefamandole nafate 554mg equivalent to 500 mg cephamandole (added as intermediate with sod bic) excipient: sodium carbonate

Canada - English - Health Canada

eli lilly canada inc - cefamandole nafate - powder for solution - 2g - cefamandole nafate 2g - second generation cephalosporins

Canada - English - Health Canada

eli lilly canada inc - cefamandole nafate - powder for solution - 1g - cefamandole nafate 1g - second generation cephalosporins

Ireland - English - HPRA (Health Products Regulatory Authority)

eli lilly and company limited - cefamandole nafate - pdr for soln for injection - 2.0 grams